Atorvastatin treatment affects atrial ion currents and their tachycardia-induced remodeling in rabbits

Life Sciences

Volumn 87, Issue 15-16, 2010, Pages 507-513

  Laszlo, Roman ^a   Menzel, Karen Anna ^a   Bentz, Kerstin ^a   Schreiner, Birgit ^a   Kettering, Klaus ^a   Eick, Christian ^a   Schreieck, Juergen ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Atorvastatin; Atrial fibrillation; Atrial remodeling; Inflammation; Oxidative stress; Patch clamp; Rabbit model; Upstream therapy

Indexed keywords

ATORVASTATIN; CALCIUM CHANNEL L TYPE; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ION CHANNEL; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PATCH CLAMP; RABBIT; TACHYCARDIA; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; ATRIAL FIBRILLATION; DRUG EFFECTS; HEART ATRIUM; METABOLISM; PATCH CLAMP TECHNIQUE; PATHOPHYSIOLOGY; TIME;

ANIMALS; ATRIAL FIBRILLATION; FEMALE; HEART ATRIA; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; ION CHANNELS; OXIDATIVE STRESS; PATCH-CLAMP TECHNIQUES; PYRROLES; RABBITS; TACHYCARDIA; TIME FACTORS;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 77957778832     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.09.010     Document Type: Article

References (58)

1. Adam O., Neuberger H.R., Bohm M., Laufs U. Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Circulation 2008, 118(12):1285-1293.
2. Allessie M., Ausma J., Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovascular Research 2002, 54(2):230-246.
3. Beltowski J. Statins and modulation of oxidative stress. Toxicology Mechanisms and Methods 2005, 15(2):61-92.
4. Beltowski J., Wojcicka G., Jamroz-Wisniewska A. Adverse effects of statins-mechanisms and consequences. Current Drug Safety 2009, 4(3):209-228.
5. Bosch R.F., Zeng X., Grammer J.B., Popovic K., Mewis C., Kuhlkamp V. Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovascular Research 1999, 44(1):121-131.
6. Bosch R.F., Scherer C.R., Rub N., Wohrl S., Steinmeyer K., Haase H., Busch A.E., Seipel L., Kuhlkamp V. Molecular mechanisms of early electrical remodeling: transcriptional downregulation of ion channel subunits reduces I(Ca, L) and I(to) in rapid atrial pacing in rabbits. Journal of the American College of Cardiology 2003, 41(5):858-869.
7. Cai H., Li Z., Goette A., Mera F., Honeycutt C., Feterik K., Wilcox J.N., Dudley S.C., Harrison D.G., Langberg J.J. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation 2002, 106(22):2854-2858.
8. Cai H., Griendling K.K., Harrison D.G. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends in Pharmacological Sciences 2003, 24(9):471-478.
9. Chung M.K., Martin D.O., Sprecher D., Wazni O., Kanderian A., Carnes C.A., Bauer J.A., Tchou P.J., Niebauer M.J., Natale A., Van Wagoner D.R. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001, 104(24):2886-2891.
10. Fehr M., Sassenburg L., Zwart P. Krankheiten der Heimtiere (diseases of domestic animals) 2005, 4. Schlütersche Verlagsgesellschaft mbH & Co KG, Hannover.
11. Frustaci A., Chimenti C., Bellocci F., Morgante E., Russo M.A., Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997, 96(4):1180-1184.
12. Fuster V., Ryden L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., Halperin J.L., Le Heuzey J.Y., Kay G.N., Lowe J.E., Olsson S.B., Prystowsky E.N., Tamargo J.L., Wann S., Smith S.C., Jacobs A.K., Adams C.D., Anderson J.L., Antman E.M., Hunt S.A., Nishimura R., Ornato J.P., Page R.L., Riegel B., Priori S.G., Blanc J.J., Budaj A., Camm A.J., Dean V., Deckers J.W., Despres C., Dickstein K., Lekakis J., McGregor K., Metra M., Morais J., Osterspey A., Zamorano J.L. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006, 8(9):651-745.
13. Hadi H.A., Mahmeed W.A., Suwaidi J.A., Ellahham S. Pleiotropic effects of statins in atrial fibrillation patients: the evidence. Vascular Health and Risk Management 2009, 5(3):533-551.
14. Hool L.C. Evidence for the regulation of L-type Ca2+ channels in the heart by reactive oxygen species: mechanism for mediating pathology. Clinical and Experimental Pharmacology & Physiology 2008, 35(2):229-234.
15. Ichiki T., Takeda K., Tokunou T., Iino N., Egashira K., Shimokawa H., Hirano K., Kanaide H., Takeshita A. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2001, 21(12):1896-1901.
16. Issac T.T., Dokainish H., Lakkis N.M. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. Journal of the American College of Cardiology 2007, 50(21):2021-2028.
17. Kamp T.J., Hell J.W. Regulation of cardiac L-type calcium channels by protein kinase A and protein kinase C. Circulation Research 2000, 87(12):1095-1102.
18. Kim Y.M., Guzik T.J., Zhang Y.H., Zhang M.H., Kattach H., Ratnatunga C., Pillai R., Channon K.M., Casadei B. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circulation Research 2005, 97(7):629-636.
19. Koebe J., Kirchhof P. Novel non-pharmacological approaches for antiarrhythmic therapy of atrial fibrillation. Europace 2008, 10(4):433-437.
20. Korantzopoulos P., Kokkoris S. The antioxidant effects of statins may extend beyond atherosclerosis: potential benefits for atrial fibrillation and heart failure. Atherosclerosis 2004, 175(1):187.
21. Korantzopoulos P., Kolettis T., Siogas K., Goudevenos J. Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Medical Science Monitor 2003, 9(9). RA225-229.
22. Korantzopoulos P., Kolettis T.M., Galaris D., Goudevenos J.A. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. International Journal of Cardiology 2007, 115(2):135-143.
23. Kostapanos M.S., Liberopoulos E.N., Goudevenos J.A., Mikhailidis D.P., Elisaf M.S. Do statins have an antiarrhythmic activity?. Cardiovascular Research 2007, 75(1):10-20.
24. Lai L.P., Su M.J., Lin J.L., Lin F.Y., Tsai C.H., Chen Y.S., Huang S.K., Tseng Y.Z., Lien W.P. Down-regulation of L-type calcium channel and sarcoplasmic reticular Ca(2+)-ATPase mRNA in human atrial fibrillation without significant change in the mRNA of ryanodine receptor, calsequestrin and phospholamban: an insight into the mechanism of atrial electrical remodeling. Journal of the American College of Cardiology 1999, 33(5):1231-1237.
25. Laszlo R., Winkler C., Wohrl S., Wessel R.E., Laszlo S., Busch M.C., Schreieck J., Bosch R.F. Effect of verapamil on tachycardia-induced early cellular electrical remodeling in rabbit atrium. Naunyn-Schmiedeberg's Archives of Pharmacology 2007, 376(4):231-240.
26. Laszlo R., Eick C., Schwiebert M., Schreiner B., Weig H.J., Weretka S., Schreieck J. Transient outward potassium current in rabbit atrium is depressed after short-time rapid atrial pacing but recovers after a longer pacing period. General Physiology and Biophysics 2008, 27(3):174-178.
27. Laufs U. Beyond lipid-lowering: effects of statins on endothelial nitric oxide. European Journal of Clinical Pharmacology 2003, 58(11):719-731.
28. Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97(12):1129-1135.
29. Laufs U., Kilter H., Konkol C., Wassmann S., Bohm M., Nickenig G. Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovascular Research 2002, 53(4):911-920.
30. Lozano H.F., Conde C.A., Florin T., Lamas G.A. Treatment and prevention of atrial fibrillation with non-antiarrhythmic pharmacologic therapy. Heart Rhythm 2005, 2(9):1000-1007.
31. McDonald T.F., Pelzer S., Trautwein W., Pelzer D.J. Regulation and modulation of calcium channels in cardiac, skeletal, and smooth muscle cells. Physiological Reviews 1994, 74(2):365-507.
32. Meinertz T, Willems S. [Treatment of atrial fibrillation in every days practice]. Internist (Berl) 49(12), 1437-1442, 1444-1435, 2008.
33. Mihm M.J., Yu F., Carnes C.A., Reiser P.J., McCarthy P.M., Van Wagoner D.R., Bauer J.A. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001, 104(2):174-180.
34. Mitani H., Bandoh T., Ishikawa J., Kimura M., Totsuka T., Hayashi S. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. British Journal of Pharmacology 1996, 119(6):1269-1275.
35. Nattel S., Khairy P., Roy D., Thibault B., Guerra P., Talajic M., Dubuc M. New approaches to atrial fibrillation management: a critical review of a rapidly evolving field 5. Drugs 2002, 62(16):2377-2397.
36. Nattel S., Burstein B., Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circulation: Arrhythmia and Electrophysiology 2008, 1(1):62-73.
37. Nishida K., Michael G., Dobrev D., Nattel S. Animal models for atrial fibrillation: clinical insights and scientific opportunities. Europace 2010, 12(2):160-172.
38. Ommen S.R., Odell J.A., Stanton M.S. Atrial arrhythmias after cardiothoracic surgery. The New England Journal of Medicine 1997, 336(20):1429-1434.
39. Psychari S.N., Apostolou T.S., Sinos L., Hamodraka E., Liakos G., Kremastinos D.T. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. The American Journal of Cardiology 2005, 95(6):764-767.
40. Rajamannan N.M., Subramaniam M., Caira F., Stock S.R., Spelsberg T.C. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 2005, 112(9 Suppl):I229-I234.
41. Rozanski G.J., Xu Z. A metabolic mechanism for cardiac K+ channel remodelling. Clinical and Experimental Pharmacology & Physiology 2002, 29(1-2):132-137.
42. Savelieva I., Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nature Clinical Practice. Cardiovascular Medicine 2008, 5(1):30-41.
43. Senthil V., Chen S.N., Tsybouleva N., Halder T., Nagueh S.F., Willerson J.T., Roberts R., Marian A.J. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation Research 2005, 97(3):285-292.
44. Shiroshita-Takeshita A., Schram G., Lavoie J., Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004, 110(16):2313-2319.
45. Smit M.D., Van Gelder I.C. Upstream therapy of atrial fibrillation. Expert Review of Cardiovascular Therapy 2009, 7(7):763-778.
46. Takemoto M., Node K., Nakagami H., Liao Y., Grimm M., Takemoto Y., Kitakaze M., Liao J.K. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. The Journal of Clinical Investigation 2001, 108(10):1429-1437.
47. Tamargo J., Caballero R., Gomez R., Nunez L., Vaquero M., Delpon E. Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. Pharmacology & Therapeutics 2007, 114(1):107-126.
48. Tang Q., Huang J., Qian H., Chen L., Wang T., Wang H., Shen D., Wu H., Xiong R. Antiarrhythmic effect of atorvastatin on autoimmune myocarditis is mediated by improving myocardial repolarization. Life Sciences 2007, 80(7):601-608.
49. Tsai C.T., Wang D.L., Chen W.P., Hwang J.J., Hsieh C.S., Hsu K.L., Tseng C.D., Lai L.P., Tseng Y.Z., Chiang F.T., Lin J.L. Angiotensin II increases expression of alpha1C subunit of L-type calcium channel through a reactive oxygen species and cAMP response element-binding protein-dependent pathway in HL-1 myocytes. Circulation Research 2007, 100(10):1476-1485.
50. Van Wagoner D.R., Pond A.L., McCarthy P.M., Trimmer J.S., Nerbonne J.M. Outward K+ current densities and Kv1.5 expression are reduced in chronic human atrial fibrillation. Circulation Research 1997, 80(6):772-781.
51. Van Wagoner D.R., Pond A.L., Lamorgese M., Rossie S.S., McCarthy P.M., Nerbonne J.M. Atrial L-type Ca2+ currents and human atrial fibrillation. Circulation Research 1999, 85(5):428-436.
52. Vaquero M., Caballero R., Gomez R., Nunez L., Tamargo J., Delpon E. Effects of atorvastatin and simvastatin on atrial plateau currents. Journal of Molecular and Cellular Cardiology 2007, 42(5):931-945.
53. Wang Z., Feng J., Shi H., Pond A., Nerbonne J.M., Nattel S. Potential molecular basis of different physiological properties of the transient outward K+ current in rabbit and human atrial myocytes. Circulation Research 1999, 84(5):551-561.
54. Wassmann S., Laufs U., Baumer A.T., Muller K., Konkol C., Sauer H., Bohm M., Nickenig G. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Molecular Pharmacology 2001, 59(3):646-654.
55. Watanabe T., Takeishi Y., Hirono O., Itoh M., Matsui M., Nakamura K., Tamada Y., Kubota I. C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. Heart and Vessels 2005, 20(2):45-49.
56. Wijffels M.C., Kirchhof C.J., Dorland R., Allessie M.A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995, 92(7):1954-1968.
57. Workman A.J., Kane K.A., Rankin A.C. Cellular bases for human atrial fibrillation. Heart Rhythm 2008, 5(6 Suppl):S1-S6.
58. Yue L., Feng J., Gaspo R., Li G.R., Wang Z., Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circulation Research 1997, 81(4):512-525.